210 related articles for article (PubMed ID: 20074162)
1. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
2. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
3. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.
Dakin GF; Warner RR; Pomp A; Salky B; Inabnet WB
J Surg Oncol; 2006 Apr; 93(5):368-72. PubMed ID: 16550587
[TBL] [Abstract][Full Text] [Related]
4. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
[TBL] [Abstract][Full Text] [Related]
5. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
6. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
8. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
Goebel SU; Serrano J; Yu F; Gibril F; Venzon DJ; Jensen RT
Cancer; 1999 Apr; 85(7):1470-83. PubMed ID: 10193936
[TBL] [Abstract][Full Text] [Related]
10. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study.
Thomas D; Tsolakis AV; Grozinsky-Glasberg S; Fraenkel M; Alexandraki K; Sougioultzis S; Gross DJ; Kaltsas G
Eur J Endocrinol; 2013 Feb; 168(2):185-93. PubMed ID: 23132699
[TBL] [Abstract][Full Text] [Related]
12. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours.
Grozinsky-Glasberg S; Kaltsas G; Gur C; Gal E; Thomas D; Fichman S; Alexandraki K; Barak D; Glaser B; Shimon I; Gross DJ
Eur J Endocrinol; 2008 Oct; 159(4):475-82. PubMed ID: 18662970
[TBL] [Abstract][Full Text] [Related]
13. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
14. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
16. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue.
Manfredi S; Pagenault M; de Lajarte-Thirouard AS; Bretagne JF
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):1021-5. PubMed ID: 18049175
[TBL] [Abstract][Full Text] [Related]
17. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release.
Fykse V; Sandvik AK; Waldum HL
Scand J Gastroenterol; 2005 Nov; 40(11):1269-74. PubMed ID: 16334435
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
19. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
Schran HF; Hager DF
Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
[No Abstract] [Full Text] [Related]
20. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
